Briefing
Liquid Biopsies with Circulating Plasma HPV-DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
In 72 patients with HPV+/p16+ OPSCC, baseline plasma cfHPV-DNA sensitivity was 97.2%; none of 41 patients with persistently undetectable follow-up cfHPV-DNA recurred, and cfHPV-DNA was detectable 97–166 days before proven recurrence.
- Design: Evidence level 3
- Assay: Not named in the abstract
Clin Cancer ResPubMed 37477909DOI 10.1158/1078-0432.CCR-23-1064